Oragenics, Inc. Files 2008 Form 10-K

Oragenics' Form 10-K includes the audited financial statements as of December 31, 2008 and notes thereto and Management's Discussion and Analysis or Plan of Operation, as well as the report of the independent registered public accounting firm dated March 31, 2009.

Oragenics makes available free of charge on its website, at www.oragenics.com, its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports as soon as reasonably practicable after Oragenics electronically files or furnishes such materials to the SEC. All of these documents will be made available free of charge on Oragenics' website, at www.oragenics.com, and will be provided free of charge to any shareholders requesting a copy by writing to: Oragenics, Inc., 13700 Progress Boulevard, Alachua, Florida 32615, U.S.A., Attention: Chief Financial Officer. These documents are also available on the SEC's website at www.sec.gov.

About Oragenics, Inc.

Oragenics, Inc., is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The company is located in Alachua, Florida, U.S.A., approximately 15 miles from the campus of the University of Florida in Gainesville.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company's current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

SOURCE: Oragenics, Inc.

Oragenics, Inc. 
David Hirsch, CEO and CFO, + 1 386 418 4018, Ext. 232 
dhirsch@oragenics.com 
or 
SSA Public Relations 
Steve Syatt, 818-907-5929 
ssyatt@ssapr.com 
or 
Cara Downs 
cdowns@ssapr.com 
or 
NewCap 
Financial Communication and Investor Relations 
Axelle Vuillermet/Pierre Laurent, + 33 (0)1 44 71 94 94 
plaurent@newcap.fr